Dupixent 300 MG/2 ML pen 2ML
Ended Awarded
- Contract number
- SPE2DB26FJEV1
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $1,980
Award facts
- Contract value 100% obligated
- $1,980.42 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,980.42 to AmerisourceBergen Drug Corp for DUPIXENT 300 MG/2 ML pen auto-injectors on October 29, 2025, with an ultimate completion date of October 30, 2025. This is a firm fixed price, non-set-aside delivery order under a competitively awarded contract vehicle. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving as a critical vendor for federal medical procurement, particularly for military and veteran healthcare systems. The company holds a significant Indefinite Delivery Contract (IDC) with DLA Troop Support Medical designated SPE2DX, valued at $999,999,999.00 and extending through December 2026, which serves as the underlying vehicle for this delivery order.
This contract represents part of AmerisourceBergen's extensive federal pharmaceutical supply portfolio with the DLA Medical Supply Chain, demonstrating the company's capability to fulfill specialized medication needs across military healthcare programs. DUPIXENT (dupilumab) is a biologic medication commonly used to treat moderate-to-severe eczema, asthma, and chronic rhinosinusitis, and this delivery order supplies the medication in pre-filled pen format for federal healthcare beneficiaries. The award reflects the company's role as a preferred vendor in the DLA's pharmaceutical procurement ecosystem and its ability to deliver specialized pharmaceutical products to support military and federal healthcare operations on compressed timelines.
Quick answers
Who was awarded contract SPE2DB26FJEV1?
SPE2DB26FJEV1 was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on October 29, 2025.
How much is contract SPE2DB26FJEV1 worth?
The government has obligated $1,980 on SPE2DB26FJEV1.
Is contract SPE2DB26FJEV1 an order under another contract?
Yes. SPE2DB26FJEV1 is a delivery order under SPE2DB22D2005, an indefinite delivery contract.
Was contract SPE2DB26FJEV1 competed?
The extent of competition for SPE2DB26FJEV1 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award